Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating) COO Jennifer Jarrett sold 12,677 shares of the company’s stock in a transaction that occurred on Friday, September 16th. The stock was sold at an average price of $26.28, for a total value of $333,151.56. Following the completion of the sale, the chief operating officer now owns 130,942 shares in the company, valued at approximately $3,441,155.76. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Arcus Biosciences Stock Performance
RCUS stock opened at $26.55 on Wednesday. Arcus Biosciences, Inc. has a 1 year low of $16.74 and a 1 year high of $49.10. The stock’s 50 day moving average price is $26.33 and its 200 day moving average price is $26.66. The firm has a market cap of $1.92 billion, a P/E ratio of 37.39 and a beta of 0.75.
Arcus Biosciences (NYSE:RCUS – Get Rating) last posted its earnings results on Wednesday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.93). Arcus Biosciences had a return on equity of 9.12% and a net margin of 16.34%. The firm had revenue of $26.76 million for the quarter, compared to analyst estimates of $21.00 million. During the same quarter in the prior year, the company earned ($1.09) EPS. On average, research analysts predict that Arcus Biosciences, Inc. will post -4.15 earnings per share for the current year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the company. Wedbush lowered their price target on Arcus Biosciences from $42.00 to $36.00 and set an “outperform” rating on the stock in a report on Thursday, August 4th. Truist Financial lowered their price target on Arcus Biosciences from $77.00 to $50.00 and set a “buy” rating on the stock in a report on Friday, July 8th. Citigroup lowered their price target on Arcus Biosciences from $48.00 to $40.00 in a report on Thursday, August 18th. SVB Leerink lowered their price target on Arcus Biosciences from $66.00 to $49.00 and set an “outperform” rating on the stock in a report on Thursday, August 4th. Finally, Cantor Fitzgerald lowered their price target on Arcus Biosciences from $62.00 to $48.00 in a report on Thursday, August 4th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $47.13.
Arcus Biosciences Company Profile
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy.
- Get a free copy of the StockNews.com research report on Arcus Biosciences (RCUS)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Has AMD stock stock fallen too far?
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.